PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportspurpura
MeSH D011693 - purpura
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D012877:Skin manifestations
0 Companies
0 Drugs
Success rate
D006470:Hemorrhage
34 Companies
13 Drugs
$
Success rate
D001778:Blood coagulation disorders
0 Companies
0 Drugs
Success rate
D011693: 
Purpura
5 Companies
1 Drug
$
Success rate
D011694:Hyperglobulinemic purpura
0 Companies
0 Drugs
Success rate
D011695:Iga vasculitis
0 Companies
0 Drugs
Success rate
D011696:Thrombocytopenic purpura
1 Company
1 Drug
$
Success rate
D014884:Waterhouse-friderichsen syndrome
0 Companies
0 Drugs
Success rate
D055665:Purpura fulminans
1 Company
0 Drugs
Success rate
Events Timeline
Loading
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
0%
0/0
Phase 2
0%
0/3
Phase 3
33%
1/3
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Actelion
Epoprostenol
GSK
Epoprostenol,
Antithrombin iii,
Sodium chloride,
Sodium lactate,
TOTROMBOPAG,
Microcrystalline cellulose,
Amg531,
Corticoids,
Octagam,
Solumedrol,
Arm1,
Arm2
Mylan
Epoprostenol
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use